

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|---------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| | | | Examiner Name | Kolker, Daniel E. | |
| Sheet | 1 | of | 16 | Attorney Docket Number | 1386/23 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| | 1 | US-4,016,043 | 04-5-1977 | Schuurs et al. | |
| | 2 | US-4,172,124 | 10-23-1979 | Koprowski et al. | |
| | 3 | US-4,474,893 | 10-02-1984 | Reading | |
| | 4 | US-4,971,903 | 11-20-1990 | Hyman | |
| | 5 | US-5,331,573 | 07-19-1994 | Balaji et al. | |
| | 6 | US-5,579,250 | 11-26-1996 | Balaji et al. | |
| | 7 | US-2001/018465 | 11-24-2000 | McGill University | |
| | 8 | US-6,331,614 | 12-18-2001 | Wong et al. | |
| | 9 | US-2003/0157525 | 11-21-2003 | Mintier et al. | |
| | 10 | US-2004/0096886 | 05-20-2004 | Rouleau et al. | |
| | 11 | US 2004-0110706 | 06-10-2004 | Wallace et al. | |
| | 12 | US-2004/0214195 | 10-28-2004 | Rouleau et al. | |
| | 13 | U8-2004/0229257 | 11-18-2004 | Petrou et al. | |
| | 14 | US 2005-0074764 | 04-07-2005 | Mulley et al. | |
| | 15 | US-2006-0089306 | 04-27-2006 | Wallace et al. | |
| | 16 | US-7,078,515 | 07-18-2006 | Wallace et al. | |
| | 17 | US-2006-0252121 | 11-09-2006 | Wallace et al. | |
| | 18 | US-7,282,336 | 10-16-2007 | Wallace et al. | |
| | 19 | US-2010/0088778 | 04-08-2010 | Mulley et al. | |
| | 20 | US-7,709,225 | 05-24-2010 | Wallace et al. | |
| | 21 | US-7,723,027 | 05-25-2010 | Petrou et al. | |
| | | | | | |
| | | | | | |
| | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|---------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| | | | Examiner Name | Kolker, Daniel E. | |
| Sheet | 2 | of | 16 | Attorney Docket Number | 1386/23 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | 22 | WO84/03564 | 09-13-1984 | Commonwealth Serum Laboratories Commission | | |
| | 23 | AU656247 | 06-28-1996 | Women's and Children's Hospital | | |
| | 24 | WO97/02048 | 01-23-1997 | Millennium Pharmaceuticals, Inc. | | |
| | 25 | WO 2001/38564 | 05-31-2001 | McGill University, CA | | |
| | 26 | WO01/88125 | 11-22-2001 | Bionomics Limited | | |
| | 27 | WO01/98486 | 12-27-2001 | Bionomics Limited | | |
| | 28 | WO 2002/006521 | 01-24-2002 | Bionomics Limited | | |
| | 29 | WO 2002/050096 | 06-27-2002 | Bionomics Limited | | |
| | 30 | WO03/008574 | 01-30-2003 | Mulley | | |
| | 31 | WO 2004/085674 | 10-07-2004 | Bionomics Limited | | |
| | 32 | WO 2005/014863 | 02-17-2005 | Bionomics Limited | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 3 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 33 | Abstracts of Decisions. Decision of a Delegate of the Commissioner of Patents corresponding to an Australian Patent Application No. 18465/01 issued January 29, 2007. | |
| | 34 | Alekov et al., "A sodium channel mutation causing epilepsy in man exhibits subtle defects in fast inactivation and activation <i>in vitro</i> ," Journal of Physiology, Vol. 529, No. 3, pgs. 533-539 (2000). | |
| | 35 | Andermann, "Multifactorial Inheritance of Generalized and Focal Epilepsy," Genetic Basis of the Epilepsies, pgs. 355-374 (1982). | |
| | 36 | Annegers, "The Epidemiology of Epilepsy," The Treatment of Epilepsy: Principles and Practice, Chpt. 11, pgs. 165-172 (1996). | |
| | 37 | Baulac et al., "A Second Locus for Familial Generalized Epilepsy with Febrile Seizures Plus Maps to Chromosome 2q21-q33," Am. J. Hum. Genet., Vol. 65, pgs. 1078-1085 (1999). | |
| | 38 | Bell and Lathrop, "Multiple loci for multiple sclerosis," Nature Genetics, Vol. 13, pgs. 377-378 (August 1996). | |
| | 39 | Bendahhou et al., "Activation and Inactivation of the Voltage-Gated Sodium Channel: Role of Segment S5 Revealed by a Novel Hyperkalaemic Periodic Paralysis Mutation," J. Neurosci., Vol. 19, pgs. 4762-4771 (1999). | |
| | 40 | Berkovic et al., "Concepts of absence epilepsies: Discrete syndromes or biological continuum?" Neurology, Vol. 37, No. 6, pgs. 993-1000 (June 1987). | |
| | 41 | Berkovic et al., "Familial Epilepsies in Israel: Clinical Syndromes and Modes of Inheritance," Neurology, Vol. 54, Suppl. 3, A356, No. P05.063 (April 2000). | |
| | 42 | Berkovic et al., "The epilepsies: specific syndromes or a neurobiological continuum?" Epileptic Seizures and Syndromes, Chpt. 5, pgs. 25-37 (1994). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 4 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 43 | Bertrand et al., "Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy," British J. of Pharmacology, Vol. 124, pgs. 1-10 (1998). | |
| | 44 | Bievert et al., "A Potassium Channel Mutation in Neonatal Human Epilepsy," Science, Vol. 279, pgs. 403-406 (January 16, 1998). | |
| | 45 | Bourgeois, "Chronic Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsy," Epilepsia, 44 (Suppl. 2), pgs. 27-32 (2003). | |
| | 46 | Cannon, "Sodium Channel Gating: No Margin for Error," Neuron, Vol. 34, pgs. 853-858 (June 13, 2002). | |
| | 47 | Cavazzuti et al., "Longitudinal Study of Epileptiform EEG Patterns in Normal Children," Epilepsia, Vol. 21, pgs. 43-55 (1980). | |
| | 48 | Charlier et al., "A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family," Nature Genetics, Vol. 18, pgs. 53-55 (January 1998). | |
| | 49 | Chou et al., "The lack of association between febrile convulsions and polymorphisms in SCN1A," Epilepsy Research, Vol. 54, pgs. 53-57 (2003). | |
| | 50 | Claes et al., "De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy," American Journal of Human Genetics, Vol. 68, pgs. 1327-1332 (2001). | |
| | 51 | Collins, "Positional cloning moves from perditional to traditional," Nature Genetics, Vol. 9, pgs. 347-349 (April 1995). | |
| | 52 | Commission on Classification and Terminology of the International League Against Epilepsy, "Proposal for Revised Classification of Epilepsies and Epileptic Syndromes," Epilepsia, Vol. 30, No. 4, pgs. 389-399 (1989). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | |
|--|---|----|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Application Number | 10/567,424 |
| | | | Filing Date | 12/9/2008 |
| | | | First Named Inventor | Mulley et al. |
| | | | Art Unit | 1649 |
| | | | Examiner Name | Kolker, Daniel E. |
| (Use as many sheets as necessary) | | | Attorney Docket Number | 1386/23 |
| Sheet | 5 | of | 16 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 53 | Communication pursuant to Rule 46(1) EPC corresponding to European Application No. 04718885.9-2402 PCT/AU2004000295 dated July 14, 2006. | |
| | 54 | DATABASE UniProt, "Sodium channel protein type I alpha subunit," XP002313393, retrieved from EBI accession no., UNIPROT: CIN1_HUMAN, Database accession no. P35498. (ABSTRACT) | |
| | 55 | DePalma, A., "Capturing Proteins Using Antibody Arrays," from Genomics and Proteomics; available online from author at www.adeplama.com, pgs. 1-5. | |
| | 56 | Doose and Baier, "Genetic Aspects of Childhood Epilepsy," Cleveland Clinic Journal of Medicine, Vol. 56, Suppl. Part 1, S101-S110 (1989). | |
| | 57 | Doose and Baier, "Genetic Factors in Epilepsies with Primarily Generalized Minor Seizures," Neuropediatrics, Vol. 18, Suppl. I, pgs. 1-64 (February 1987). | |
| | 58 | Dworakowska and Dolowy, "Ion channels-related diseases," ACTA Biochimica Polonica, Vol. 47, No. 3, pgs. 685-703 (2000). | |
| | 59 | Escayg et al., "Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2," Nature Genetics, Vol. 24, pgs. 343-345 (April 2000). | |
| | 60 | European Patent Office Search Report corresponding to European Patent Application No. 07075566.5 - 2401 dated October 4, 2007. | |
| | 61 | Examiner's First Report for Australian Patent Application No. 2004200978 dated May 6, 2004. | |
| | 62 | Finkelstein et al., "Use of denaturing gradient gel electrophoresis for detection of mutation and prospective diagnosis in late onset ornithine transcarbamylase deficiency," Genomics, Vol. 7, pgs. 167-172 (1990). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 6 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 63 | Fong et al., "Childhood Absence Epilepsy with Tonic-Clonic Seizures and Electroencephalogram 3-4-Hz Spike and Multispike-Slow Wave Complexes: Linkage to Chromosome 8q24," Am. J. Hum. Genet., Vol 63, pgs. 1117-1129 (1998). | |
| | 64 | Fujiwara et al., "Long-Term Course of Childhood Epilepsy with Intractable Grand Mal Seizures," Jpn. J. Psychiatry Neurol., Vol. 46, pgs. 297-302 (1992). | |
| | 65 | Fukuma G., "Mutations of neuronal voltage-gated Na ⁺ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB)," Epilepsia, Vol. 45, No. 2, pgs. 140-148 (February 2004). | |
| | 66 | Gardiner, "Impact of our understanding of the genetic aetiology of epilepsy," J. Neurol., Vol. 247, pgs. 327-334 (2000). | |
| | 67 | Genbank accession number AB093548. | |
| | 68 | Genbank accession number M22253. | |
| | 69 | Genbank accession number NM_012647. | |
| | 70 | Genbank Accession No. NM_172107. | |
| | 71 | GenBank Locus AF225985, "Homo sapiens voltage-gated sodium channel alpha subunit SCN1A (SCN1A) mRNA, complete cds," pgs. 1-4 (Feb. 1, 2001). | |
| | 72 | GenBank Locus NM_006920, "Homo sapiens sodium channel, voltage-gated, type I, alpha (SCN1A), mRNA," pgs. 1-11 (Nov. 13, 2006). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 7 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 73 | Gene Card for SCNA1 available via uri: <genecards.org/cgi-bin/carddisp.pl?gene=SCN1A> | |
| | 74 | GeneCards output for protein-coding SCN1A, available online from www.genecards.org, pgs. 1-20. | |
| | 75 | Gennaro et al., "Familial severe myoclonic epilepsy of infancy: truncation of Na _v 1.1 and genetic heterogeneity," <i>Epileptic Disord.</i> , Vol. 5, pgs. 21-25 (2003). | |
| | 76 | Geysen H.M. et al., "Cognitive features of continuous antigenic determinants," <i>Journal of Molecular Recognition</i> , Vol. 1, pgs. 32-41 (1988). | |
| | 77 | Goldsby et al., "Immunology," Fifth Edition, section "Cross-Reactivity," pg. 141 (2003). | |
| | 78 | Greenberg et al., "Evidence for multiple gene loci in the expression of the common generalized epilepsies," <i>Neurology</i> , Vol. 42, Suppl. 5, pgs. 56-62 (April 1992). | |
| | 79 | Greenberg et al., "Juvenile Myoclonic Epilepsy (JME) May be Linked to the BF and HLA Loci on Human Chromosome 6," <i>Am. J. of Medical Genetics</i> , Vol. 31, pgs. 185-192 (1988). | |
| | 80 | Greenberg et al., "Segregation Analysis of Juvenile Myoclonic Epilepsy," <i>Genetic Epidemiology</i> , Vol. 5, pgs. 81-94 (1988). | |
| | 81 | Guerrini et al., "Lamotrigine and seizure aggravation in severe myoclonic epilepsy, Epilepsia, Vol. 39s, pgs. 508-512 (1998). | |
| | 82 | Harkin et al., "The Spectrum of SCN1A-Related Infantile Epileptic Encephalopathies," <i>Brain</i> , Vol. 130, pgs. 843-852 (2007). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 8 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 83 | Hauser et al., "Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935-1984," <i>Epilepsia</i> , Vol. 34, No. 3, pgs. 453-468 (1993). | |
| | 84 | Hille, "Ionic Channels of Excitable Membranes," 2 nd Edition, pgs. 423 and 434-444 (1992). | |
| | 85 | Hirschhorn et al., "A comprehensive review of genetic association studies," <i>Genetics in Medicine</i> , Vol. 4, No. 2, pgs. 45-61 (2002). | |
| | 86 | International Search Report for International Application No. PCT/AU2004/000295 dated May 14, 2004. | |
| | 87 | Interview Summary corresponding to U.S. Patent Application Serial No. 11/262,647 dated December 5, 2008. | |
| | 88 | Interview Summary corresponding to U.S. Patent Application Serial No. 10/806,899 dated November 23, 2009. | |
| | 89 | Interview Summary corresponding to U.S. Patent Application Serial No. 10/806,899 dated October 8, 2009. | |
| | 90 | Interview Summary corresponding to U.S. Patent Application Serial No. 10/806,899 dated November 1, 2007. | |
| | 91 | Janz et al., "Do idiopathic generalized epilepsies share a common susceptibility gene?" <i>Neurology</i> , Vol. 42, Suppl 5, pgs. 48-55 (April 1992). | |
| | 92 | Kanai et al., "Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity," <i>Neurology</i> , Vol. 63, pgs. 329-334 (2004). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | |
|--|---|----|-------------------------------|-------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Application Number | 10/567,424 |
| | | | Filing Date | 12/9/2008 |
| | | | First Named Inventor | Mulley et al. |
| | | | Art Unit | 1649 |
| | | | Examiner Name | Kolker, Daniel E. |
| (Use as many sheets as necessary) | | | Attorney Docket Number | 1386/23 |
| Sheet | 9 | of | 16 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 93 | Kimura K., "A missense mutation in SCN1A in brothers with severe myoclonic epilepsy in infancy (SMEI) inherited from a father with febrile seizures," Brain Dev., Vol. 27, No. 6, pgs. 424-430 (September 2005). | |
| | 94 | Kinzler et al., "Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers," Science, Vol. 251, pgs. 1366-1370 (1991). | |
| | 95 | Kuhn et al., "Movement of voltage sensor S4 in domain 4 is tightly coupled to sodium channel fast inactivation and gating charge immobilization," J. Gen. Physiol., Vol. 114, pgs. 167-183 (1999). | |
| | 96 | Lason W., "Neurochemical and pharmacological aspects of cocaine-induced seizures," Polish Journal of Pharmacology, Vol. 53, pgs. 57-60 (2001). | |
| | 97 | Lerche et al., "Ion Channels and Epilepsy," Am. J. of Med. Genetics, Vol. 106, pgs. 146-159 (2001). | |
| | 98 | Lernmark and Ott, "Sometimes it's hot, sometimes it's not," Nature Genetics, Vol. 19, pgs. 213-214 (July 1998). | |
| | 99 | Lo et al., "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," Protein Engineering, Vol. 11, pgs. 495-500 (1998). | |
| | 100 | Lopes-Cendes et al., "A New Locus for Generalized Epilepsy with Febrile Seizures Plus Maps to Chromosome 2," Am. J. Hum. Genet., Vol. 66, pgs. 698-701 (2000). | |
| | 101 | Lucentini, J., "Gene Association Studies Typically Wrong," The Scientist, pg. 20 (December 20, 2004). | |
| | 102 | Madia et al., "No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancy," Epilepsy Research, Vol. 53, pgs. 196-200 (2003). | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 10 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 103 | Malacarne et al., "Lack of SCN1A Mutations in Familial Febrile Seizures," <i>Epilepsia</i> , Vol. 43, No. 5, pgs. 559-562 (2002). | |
| | 104 | Maxam et al., "A new method for sequencing DNA," <i>Proceedings of the National Academy of Sciences of the USA</i> , Vol. 74, No. 2, pgs. 560-564 (1977). | |
| | 105 | Mazumder et al., "Translations control by the 3'-UTR: the ends specify the means," <i>Trends in Biochemical Sciences</i> , Vol. 28, pgs. 91-98 (2004). | |
| | 106 | Modrich, Paul, "Mechanisms and biological effects of mismatch repair," <i>Annual Review of Genetics</i> , Vol. 25, pgs. 229-253 (1991). | |
| | 107 | Moran et al., "Skeletal Muscle Sodium Channel Is Affected by an Epileptogenic $\beta 1$ Subunit Mutation," <i>Biochem. Biophys. Res. Comm.</i> , Vol. 282, pgs. 55-59 (2001). | |
| | 108 | Moulard et al., "Identification of a New Locus for Generalized Epilepsy with Febrile Seizures Plus (GEFS+) on Chromosome 2q24-q33," <i>Am. J. Hum. Genet.</i> , Vol. 65, pgs. 1396-1400 (1999). | |
| | 109 | Mulley et al., "SCN1A Mutations and Epilepsy," <i>Human Mutation</i> , Vol. 25, pgs. 535-542 (2005). | |
| | 110 | Mulley et al., "Channelopathies as a Genetic Cause of Epilepsy," <i>Current Opinion in Neurology</i> , Vol. 16, pgs. 171-176 (2003). | |
| | 111 | Notice of Allowance corresponding to U.S. Patent Application Serial No. 10/451,126 (Patent No. 7,078,515) dated August 30, 2005. | |
| | 112 | Notice of Allowance corresponding to U.S. Patent Application Serial No. 11/263,326 (Patent No. 7,282,336) dated June 18, 2007. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 11 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 113 | Notice of Allowance corresponding to U.S. Patent Application Serial No. 11/262,647 dated December 18, 2009. | |
| | 114 | Notice of Allowance corresponding to U.S. Patent Application Serial No. 10/806,899 dated January 4, 2010. | |
| | 115 | Notification Concerning Transmittal of Copy of International Preliminary Report on Patentability for International Application No. PCT/AU2006/000841 dated January 3, 2008. | |
| | 116 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated August 7, 2009. | |
| | 117 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated December 30, 2008. | |
| | 118 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated April 4, 2008. | |
| | 119 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated August 2, 2007. | |
| | 120 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated October 28, 2009. | |
| | 121 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated May 13, 2009. | |
| | 122 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated August 19, 2008. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|-------------------|----|----|--------------------------|---------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/567,424 |
| | | | | Filing Date | 12/9/2008 |
| | | | | First Named Inventor | Mulley et al. |
| | | | | Art Unit | 1649 |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 12 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 123 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated June 26, 2007. | |
| | 124 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated November 29, 2006. | |
| | 125 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/263,326 (Patent No. 7,282,336) dated October 6, 2006. | |
| | 126 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/262,647 dated April 22, 2009. | |
| | 127 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/262,647 dated December 5, 2008. | |
| | 128 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/262,647 dated February 15, 2008. | |
| | 129 | Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/451,126 (Patent No. 7,078,515) dated January 24, 2005. | |
| | 130 | Ohmori et al., "Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy," Biochemical and Biophysical Research Communications, Vol. 295, pgs. 17-23 (2002). | |
| | 131 | Ohtahara et al., "Lennox-Gastaut syndrome: a new vista," Psychiatry Clin. Neurosci., Vol. 49, pgs. S179-S183 (1995). | |
| | 132 | Ohtsuka et al., "Long-term prognosis of the Lennox-Gastaut syndrome," Jpn. J. Psychiatry Neurol., Vol. 44, pgs. 257-264 (1990). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 13 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 133 | Ohtsuka et al., "Refractory Childhood Epilepsy and Factors Related to Refractoriness," <i>Epilepsia</i> , Vol. 41, Suppl. 9, pgs. 14-17 (2000). | |
| | 134 | Okubo et al., "Epileptiform EEG Discharges in Healthy Children: Prevalence, Emotional and Behavioral Correlates, and Genetic Influences," <i>Epilepsia</i> , Vol. 35, No. 4, pgs. 832-841 (1994). | |
| | 135 | Orita et al., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand confirmation polymorphisms," <i>Proceedings of the National Academy of Sciences of the USA</i> , Vol. 86, pgs. 2766-2770 (1989). | |
| | 136 | Panayiotopoulos and Obeid, "Juvenile Myoclonic Epilepsy: An Autosomal Recessive Disease," <i>Ann Neurol</i> , Vol. 25, pgs. 440-443 (1989). | |
| | 137 | Peiffer et al., "A Locus for Febrile Seizures (FEB3) Maps to Chromosome 2q23-24," <i>Annals of Neurology</i> , Vol. 46, No. 4, pgs. 671-678 (October 1999). | |
| | 138 | Phillips et al., "Autosomal Dominant Nocturnal Frontal-Lobe Epilepsy: Genetic Heterogeneity and Evidence for a Second Locus at 15q24," <i>Am. J. Hum. Genet.</i> , Vol. 63, pgs. 1108-1116 (1998). | |
| | 139 | Phillips et al., "Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2," <i>Nature Genetics</i> , Vol. 10, pgs. 117-118 (May 1995). | |
| | 140 | Plummer et al., "Evolution and Diversity of Mammalian Sodium Channel Genes," <i>Genomics</i> , Vol. 57, pgs. 323-331 (1999). | |
| | 141 | Plummer et al., "Exon Organization, Coding Sequence, Physical Mapping, and Polymorphic Intragenic Markers for the Human Neuronal Sodium Channel Gene SCN8A," <i>Genomics</i> , Vol. 54, pgs. 287-296 (1998). | |
| | 142 | Reutens and Berkovic, "Idiopathic generalized epilepsy of adolescence: Are the syndromes clinically distinct?" <i>Neurology</i> , Vol. 45, pgs. 1469-1476 (August 1995). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 14 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 143 | Risch and Botstein, "A manic depressive history," Nature Genetics, Vol. 12, pgs. 351-353 (April 1996). | |
| | 144 | Sanger et al., "DNA sequencing with chain-terminating inhibitors," Proceedings of the National Academy of Sciences of the USA, Vol. 74, No. 12, pgs. 5463-5467 (1977). | |
| | 145 | Scheffer and Berkovic, "Generalized epilepsy with febrile seizures plus A genetic disorder with heterogeneous clinical phenotypes," Brain, Vol. 120, pgs. 479-490 (1997). | |
| | 146 | Scheffer et al., "Locus for Febrile Seizures," Annals of Neurology, Vol. 47, No. 6, pgs. 840-841 (June 2000). | |
| | 147 | Scheffer et al., "The Genetics of Human Epilepsy," TRENDS in Pharmacological Science, Vol. 24, No. 8, pgs. 428-433 (August 2003). | |
| | 148 | Sheffield et al., "Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results," Proceedings of the National Academy of Sciences of the USA, Vol. 86, pgs. 232-236 (1989). | |
| | 149 | Singh et al., "A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns," Nature Genetics, Vol. 18, pgs. 25-29 (January 1998). | |
| | 150 | Singh et al., "Generalized Epilepsy with Febrile Seizures Plus: A Common Childhood-Onset Genetic Epilepsy Syndrome," Ann. Neurol., Vol. 45, pgs. 75-81 (1999). | |
| | 151 | Singh et al., "Severe Myoclonic Epilepsy of Infancy: Extended Spectrum of GEFS?" Epilepsia, Vol. 42, No. 7, pgs. 837-844 (2001). | |
| | 152 | Spampanato et al., "Generalized Epilepsy with Febrile Seizures Plus Type 2 Mutation W1204R Alters voltage-Dependent Gating of Na _v 1.1 Sodium Channels," Neuroscience, Vol. 116, pgs. 37-48 (2003). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 15 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 153 | Stafstrom et al., "Epilepsy Genes: The link between molecular dysfunction and pathophysiology", Mental Retardation and Developmental Disabilities Research Reviews, Vol. 6, pgs. 281-292 (2000). | |
| | 154 | Steinlein et al., "A missense mutation in the neuronal nicotinic acetylcholine receptor $\alpha 4$ subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy," Nature Genetics, Vol. 11, pgs. 201-203 (October 1995). | |
| | 155 | Sugawara et al., "Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy," Neurology, Vol. 58, pgs. 1122-1124 (2002). | |
| | 156 | Sugawara, T., "Nav1.1 channels with mutations of severe myoclonic epilepsy in infancy display attenuated currents," Epilepsy Res., Vol. 54, Nos. 2-3, pgs. 201-207 (May 2003). | |
| | 157 | Supplementary European Search Report corresponding to Australian Patent No. AU0200910 dated February 17, 2005. | |
| | 158 | Supplementary Partial European Search Report for Application No. 01271383.0-2406 dated March 12, 2004. | |
| | 159 | Taylor et al., "Enzymatic methods for mutation scanning," Genetic Analysis: Biomolecular Engineering, Vol. 14, pgs. 181-186 (1999). | |
| | 160 | Thisted, "What is a P-value?" available online from www.stat.uchicago.edu, pgs. 1-6 (May 25, 1998). | |
| | 161 | Todd, "Interpretation of results from genetic studies of multifactorial disease," Molecular Medicine, Vol. 354, pgs. 15-16 (July 1999). | |
| | 162 | Veggiotti et al., "Generalized Epilepsy with Febrile Seizures plus and Severe Myoclonic Epilepsy in Infancy: a case report of two Italian families," Epileptic Discord, Vol. 3, pgs. 29-32 (2001). | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|-------------------|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/567,424 | |
| | | | Filing Date | 12/9/2008 | |
| | | | First Named Inventor | Mulley et al. | |
| | | | Art Unit | 1649 | |
| Examiner Name | Kolker, Daniel E. | | | | |
| Sheet | 16 | of | 16 | Attorney Docket Number | 1386/23 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 163 | Wallace et al., "Febrile seizures and generalized epilepsy associated with a mutation in the Na ⁺ -channel β 1 subunit gene SCN1B," Nature Genetics, Vol. 19, pgs. 366-370 (August 1998). | |
| | 164 | Wallace et al., "Mutant GABA _A receptor γ 2-subunit in childhood absence epilepsy and febrile seizures," Nature Genetics, Vol. 28, pgs. 49-52 (May 2001). | |
| | 165 | Wallace et al., "Sodium Channel E L-Subunit Mutations in Severe Myoclonic Epilepsy of Infancy and Infantile Spasms," Neurology, Vol. 61, pgs. 765-769 (September 2003). | |
| | 166 | Wallace R., "A Plethora of SCN1A Mutations: What Can They Tell Us?" Epilepsy Curro., Vol. 5, No. 1, pgs. 17-20 (January 2005). | |
| | 167 | Wartell et al., "Detecting base pair substitutions in DNA fragments by temperature-gradient gel electrophoresis," Nucleic Acids Research, Vol. 18, No. 9, pgs. 2699-2705 (1990). | |
| | 168 | Zara et al., "Mapping of genes predisposing to idiopathic generalized epilepsy," Human Molecular Genetics, Vol. 4, No. 7, pgs. 1201-1207 (1995). | |
| | 169 | Zara et al., "Mapping of Locus for a Familial Autosomal Recessive Idiopathic Myoclonic Epilepsy of Infancy to Chromosome 16p13," Am. J. Hum. Genet., Vol. 66, pgs. 1552-1557 (2000). | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.